Drugs / Vigil
Vigil
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02574533 | Oct 2015 → Sep 2017 | melanoma | Gradalis, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01061840 | Dec 2009 → Dec 2018 | Ewing sarcoma, liver cancer, non-small cell lung carcinoma | Gradalis, Inc. | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT03073525 | May 2017 → May 2019 | cervical cancer, ovarian cancer | Gradalis, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02725489 | Jun 2016 → Dec 2019 | breast cancer, cervical cancer, endometrial cancer, fallopian tube cancer +2 | Mary Crowley Medical Research Center | Completed | No outcome recorded |
| Phase 2 | NCT02639234 | Mar 2016 → Mar 2017 | non-small cell lung carcinoma | Gradalis, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT02511132 | Feb 2016 → Nov 2018 | Ewing sarcoma | Gradalis, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01867086 | Jun 2013 → Apr 2016 | ovarian carcinoma | Gradalis, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01551745 | Mar 2012 → Apr 2016 | ovarian carcinoma | Gradalis, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01505166 | Mar 2012 → Aug 2016 | colorectal carcinoma | Gradalis, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01453361 | Oct 2011 → Mar 2016 | melanoma | Gradalis, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01309230 | Mar 2011 → Feb 2022 | ovarian cancer | Gradalis, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03495921 | Aug 2018 → Jan 2022 | Ewing sarcoma, bone neoplasm, connective and soft tissue neoplasm | Gradalis, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase not stated1 trial | ||||||
| — | NCT03842865 | — | Ewing sarcoma, cervical cancer, ovarian cancer | Gradalis, Inc. | Temporarily not available | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT02346747 Comparator | Feb 2015 → Dec 2028 expected | ovarian cancer | Gradalis, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01638403 Comparator | Nov 2010 → Apr 2012 | narcolepsy | Bioprojet | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vigil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03495921 ↗ |
| Known as | formerly known as FANG | “formerly known as FANG™” NCT01505166 ↗1“formerly known as FANG™” NCT02639234 ↗ |
| Known as | formerly known as FANG Vaccine | “formerly known as FANG™ Vaccine” NCT01061840 ↗ |
| Known as | Gemogenovatucel-T | “Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.” PMID 33271095 ↗ Dec 20201“Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer.” PMID 34452019 ↗ Aug 2021 |
| Action | Inhibit | “The furin bifunctional shRNA blocks furin protein production” NCT01061840 ↗ |
| Modality | Vaccine | “FANG vaccine, an autologous tumor-based product incorporating a plasmid encoding granulocyte-macrophage colony-stimulating factor (GMCSF) and a novel bifunctional short hairpin...” PMID 22186789 ↗ Dec 2011 |
| Route | Other | “via intradermal injection” NCT01309230 ↗ |
| Target | FURIN | “a novel bifunctional short hairpin RNAi (bi-shRNAi) targeting furin convertase” PMID 22186789 ↗ Dec 2011 |